April 30, 2009
Biotecnol successfully completes milestone of process development and manufacturing activities for Alligator Bioscience AB inflammation programme ADC -1004
Read more>>
Description of Activities 2008
Description of Activities 2008.pdf
Alligators presentation på RedEye´s investerarträff 24 mars 2009
Se presentationen här>>
November 25, 2008
Alligator Bioscience AB, the protein optimization company, to Present at the Rodman & Renshaw 10th Annual Healthcare Conference.
Read more >>
June 16, 2008
Alligator Bioscience AB and PolyTherics Ltd announce strategic collaboration for optimisation of next generation biopharmaceuticals
Read more >>

"We use our proprietary FIND® technology platform to discover and develop optimized protein drug candidates"



.... focusing on the treatment of Inflammation and Cancer"
ADC-1004 Protects Against
Inflammation Injury
Reperfusion injury is a serious complication after e.g. myocardial infarction treated with balloon dilatation. Alligator Bioscience has created a drug candidate, ADC-1004, that is assumed to protect against this reperfusion injury. 
READ MORE ...		  
        
ADC-1001 Second Generation IL-1Ra
Our FIND® technology has proven to be very useful in creating second generation biopharmaceuticals. Alligator Bioscience has made a second generation drug candidate of Anakinra (Kineret®) with increased receptor affinity compared to Anakinra.
READ MORE …
 
 
        
Gun-Britt Fransson, CEO
"The success of biopharmaceuticals has resulted in major pharmaceutical companies committing themselves to protein drug development. Our FIND® technology makes Alligator Bioscience the perfect partner in developing tomorrows therapies meeting patients' and doctors' needs."
    
Bengt Larsson, CMO
“ADC-1004 is a protein drug candidate optimized to be a selective antagonist of the C5a receptor. Its properties are suitable for treating acute inflammation, a condition for which there is a high unmet medical need.”
    
Eva Dahlen, Head of Discovery
“For a company like Alligator Bioscience it is crucial to maintain a continuous influx of good ideas, a scientifically skilled and creative staff to evaluate and prioritize them, and finally a unique technology platform to optimize and develop them.”

  
Christina Furebring, VP R&D
“We use our FIND® technology to redesign the protein to best suit the specific therapeutic requirements. We are not limited to native proteins or by constrains in conventional protein engineering techniques.”
 
Alligator Bioscience AB :: Scheelevägen 19A :: 223 70 Lund :: Phone: + 46 (0)46 286 4280 :: Fax: + 46 (0)46 286 4290
Copyright © 2008 Alligator Bioscience AB. All rights reserved